Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials

por Harris, Sarah, Comi, Giancarlo, Cree, Bruce A. C., Arnold, Douglas L., Steinman, Lawrence, Sheffield, James K., Southworth, Harry, Kappos, Ludwig, Cohen, Jeffrey A.
Publicado 2021

SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis

por Cree, Bruce A. C., Maddux, Rachel, Bar‐Or, Amit, Hartung, Hans‐Peter, Kaur, Amandeep, Brown, Elizabeth, Li, Yicong, Hu, Yanhua, Sheffield, James K., Silva, Diego, Harris, Sarah
Publicado 2023

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS

por Ungaro, Ryan C., Siegel, Corey A., Cree, Bruce, Selmaj, Krzysztof, Ahmad, Harris, Pai, Ashwini, Ather, Shabana, Henry, Alyssa, Charles, Lorna, Petersen, AnnKatrin, Cheng, Chun-Yen, Afsari, Sonia, Sheffield, James K., Vaile, John, Colombel, Jean Frederic
Publicado 2022

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

por Cree, Bruce AC, Selmaj, Krzysztof W, Steinman, Lawrence, Comi, Giancarlo, Bar-Or, Amit, Arnold, Douglas L, Hartung, Hans-Peter, Montalbán, Xavier, Havrdová, Eva K, Sheffield, James K, Minton, Neil, Cheng, Chun-Yen, Silva, Diego, Kappos, Ludwig, Cohen, Jeffrey A
Publicado 2022